N Wang1,2, M McKell3, A Dang1, A Yamani1, L Waggoner1, S Vanoni1, T Noah1, D Wu1, A Kordowski4, J Köhl3,4, K Hoebe3, S Divanovic3, S P Hogan1. 1. Division of Allergy and Immunology, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 2. Chongqing Health Center for Women and Children, Chongqing Shi, China. 3. Division of Immunobiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA. 4. Institute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
Abstract
BACKGROUND: Clinical and experimental analyses have identified a central role for IgE/FcεRI/mast cells in promoting IgE-mediated anaphylaxis. Recent data from human studies suggest that bacterial infections can alter susceptibility to anaphylaxis. OBJECTIVE: We examined the effect of LPS exposure on the induction of IgE-mast cell (MC) mediated reactions in mice. METHODS: C57BL/6 WT, tlr4-/- and IL10-/- mice were exposed to LPS, and serum cytokines (TNF and IL-10) were measured. Mice were subsequently treated with anti-IgE, and the symptoms of passive IgE-mediated anaphylaxis, MC activation, Ca2+ -mobilization and the expression of FcεRI on peritoneal MCs were quantitated. RESULTS: We show that LPS exposure of C57BL/6 WT mice constraints IgE-MC-mediated reactions. LPS-induced suppression of IgE-MC-mediated responses was TLR-4-dependent and associated with increased systemic IL-10 levels, decreased surface expression of FcεRI on MCs and loss of sensitivity to IgE activation. Notably, LPS-induced desensitization of MCs was short term with MC sensitivity to IgE reconstituted within 48 hours, which was associated with recapitulation of FcεRI expression on the MCs. Mechanistic analyses revealed a requirement for IL-10 in LPS-mediated decrease in MC FcεRI surface expression. CONCLUSIONS & CLINICAL RELEVANCE: Collectively, these studies suggest that LPS-induced IL-10 promotes the down-regulation of MC surface FcεRI expression and leads to desensitization of mice to IgE-mediated reactions. These studies indicate that targeting of the LPS-TLR-4-IL-10 pathway may be used as a therapeutic approach to prevent adverse IgE-mediated reactions.
BACKGROUND: Clinical and experimental analyses have identified a central role for IgE/FcεRI/mast cells in promoting IgE-mediated anaphylaxis. Recent data from human studies suggest that bacterial infections can alter susceptibility to anaphylaxis. OBJECTIVE: We examined the effect of LPS exposure on the induction of IgE-mast cell (MC) mediated reactions in mice. METHODS: C57BL/6 WT, tlr4-/- and IL10-/- mice were exposed to LPS, and serum cytokines (TNF and IL-10) were measured. Mice were subsequently treated with anti-IgE, and the symptoms of passive IgE-mediated anaphylaxis, MC activation, Ca2+ -mobilization and the expression of FcεRI on peritoneal MCs were quantitated. RESULTS: We show that LPS exposure of C57BL/6 WT mice constraints IgE-MC-mediated reactions. LPS-induced suppression of IgE-MC-mediated responses was TLR-4-dependent and associated with increased systemic IL-10 levels, decreased surface expression of FcεRI on MCs and loss of sensitivity to IgE activation. Notably, LPS-induced desensitization of MCs was short term with MC sensitivity to IgE reconstituted within 48 hours, which was associated with recapitulation of FcεRI expression on the MCs. Mechanistic analyses revealed a requirement for IL-10 in LPS-mediated decrease in MC FcεRI surface expression. CONCLUSIONS & CLINICAL RELEVANCE: Collectively, these studies suggest that LPS-induced IL-10 promotes the down-regulation of MC surface FcεRI expression and leads to desensitization of mice to IgE-mediated reactions. These studies indicate that targeting of the LPS-TLR-4-IL-10 pathway may be used as a therapeutic approach to prevent adverse IgE-mediated reactions.
Authors: J Bousquet; R Lockey; H J Malling; E Alvarez-Cuesta; G W Canonica; M D Chapman; P J Creticos; J M Dayer; S R Durham; P Demoly; R J Goldstein; T Ishikawa; K Ito; D Kraft; P H Lambert; H Løwenstein; U Müller; P S Norman; R E Reisman; R Valenta; E Valovirta; H Yssel Journal: Ann Allergy Asthma Immunol Date: 1998-11 Impact factor: 6.347
Authors: Muthuvel Arumugam; Richard Ahrens; Heather Osterfeld; Leah C Kottyan; Xun Shang; John A Maclennan; Nives Zimmermann; Yi Zheng; Fred D Finkelman; Simon P Hogan Journal: BMC Immunol Date: 2011-02-03 Impact factor: 3.615
Authors: Binh L Phong; Shaina J D'Souza; Robin L Baudier; Eric Wu; Victoria E Immethun; David L Bauer; James B McLachlan Journal: Sci Rep Date: 2021-05-06 Impact factor: 4.379
Authors: Caroline E Childs; Daniel Munblit; Laurien Ulfman; Carlos Gómez-Gallego; Liisa Lehtoranta; Tobias Recker; Seppo Salminen; Machteld Tiemessen; Maria Carmen Collado Journal: Adv Nutr Date: 2021-10-01 Impact factor: 8.701
Authors: Heather L Caslin; Kasalina N Kiwanuka; Tamara T Haque; Marcela T Taruselli; H Patrick MacKnight; Anuya Paranjape; John J Ryan Journal: Front Immunol Date: 2018-04-26 Impact factor: 7.561